Anzeige
Mehr »
Mittwoch, 29.10.2025 - Börsentäglich über 12.000 News
Die 80-Milliarden-Dollar-Nuklear-Renaissance: Warum Uran der heißeste Sektor der Welt ist
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 853849 | ISIN: JP3463000004 | Ticker-Symbol: TKD
Tradegate
29.10.25 | 08:01
24,120 Euro
-1,43 % -0,350
Branche
Chemie
Aktienmarkt
NIKKEI-225
Singapur
1-Jahres-Chart
TAKEDA PHARMACEUTICAL CO LTD Chart 1 Jahr
5-Tage-Chart
TAKEDA PHARMACEUTICAL CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
23,93024,07010:13
23,94024,09010:11

Aktuelle News zur TAKEDA PHARMACEUTICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoTakeda Says HyHub And HyHub Duo Devices Now Available In U.S. To Simplify HYQVIA Infusion Process263TOKYO (dpa-AFX) - Japan's Takeda Pharmaceutical Co. Ltd. (TAK) announced Monday that the recently FDA-approved HyHub and HyHub Duo devices are now available in the U.S. for patients 17 years...
► Artikel lesen
FrCMBI Adds INNOVENT BIO TP to $110.62 on Strategic Partnership with Takeda Pharmaceutical8
TAKEDA PHARMACEUTICAL Aktie jetzt für 0€ handeln
DoTetraScience Launches Scientific AI Lighthouse Program with Takeda as Founding Partner233Reimagining and replatforming science for the era of AI BOSTON, Oct. 23, 2025 /PRNewswire/ -- TetraScience, the Scientific Data and AI Company, today launched its...
► Artikel lesen
DoTakeda signs deal worth up to $11.4bn with Innovent for cancer drug hopefuls4
DoTakeda, Innovent Ink $11.4 Billion Cancer Drug Deal4
DoBofAS Elevates INNOVENT BIO TP to $113 as Co-op with Takeda Pharmaceutical Marks Major Step Towards Becoming Multinational Pharma Firm14
DoCLSA Lifts INNOVENT BIO's TP to HKD120.1; Takeda Pharma Co-op Positive for Product Development4
22.10.Takeda Boosts Pipeline and Revenue Growth Prospects With $1.2B Deal for Innovent Cancer Drugs8
22.10.Takeda Licenses Late-Stage Cancer Drugs from Innovent in $1.2 Billion Deal4
22.10.Takeda stakes more than $11B on cancer drugs from China4
22.10.Takeda pays Innovent $1.2B upfront for rights to 2 cancer candidates6
22.10.Takeda builds in cancer with monster $11.4bn Innovent deal2
22.10.Takeda schließt mit Innovent Lizenzvereinbarung über 11,4 Mrd. Dollar für Krebsmedikamente34
22.10.Takeda inks $11.4 billion deal with Innovent for cancer drug candidates3
22.10.China's Innovent Grants Takeda Pharma Rights to Three Cancer Drugs for Record USD11.4 Billion2
22.10.Innovent inks $11.4 billion cancer drug partnership with Japan's Takeda5
22.10.Innovent seals lucrative $11.4b deal with Takeda Pharmaceutical3
22.10.INNOVENT BIO Opens Up 10% on Shr Issuance to Takeda Pharma at ~30% Premium w/Licensing Deal Worth USD11.4B3
22.10.INNOVENT BIO Issues Shrs at ~30% Premium to Takeda Pharma w/Licensing Deal Involving USD11.4B3
22.10.Takeda And Innovent Biologics Sign Global Oncology Collaboration Outside Greater China906BEIJING (dpa-AFX) - Takeda (TAK) has signed a license and collaboration agreement with Innovent Biologics to advance the development, manufacturing, and commercialization of two late-stage oncology...
► Artikel lesen
Weiter >>
177 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2